#United States #San Diego #Seraphina Therapeutics #fatty15 #pentadecanoic acid

Dr. Stephanie Venn-Watson: A Life Sciences Visionary

The world of nutritional science has been invigorated by Dr. Stephanie Venn-Watson's exceptional contributions to understanding dietary needs, particularly for older adults. Recently, her pioneering work has earned her the title of 2026 LA Times Life Sciences Visionary. This recognition comes on the heels of her groundbreaking research into a newly identified nutritional deficiency syndrome linked to pentadecanoic acid (C150).

Dr. Venn-Watson's journey began with a seemingly simple project: enhancing the health of aging Navy dolphins. Through meticulous observation, she uncovered alarming trends; dolphins experiencing low levels of odd-chain saturated fatty acids, including C150 and C170, were quite vulnerable to serious health conditions like insulin resistance, chronic inflammation, and fatty liver disease. By adjusting the dolphins' diets to incorporate more C150, her team observed significant improvements in their overall health.

"Initially, we were unaware that these dolphins were teaching us a pivotal lesson regarding health and longevity," Dr. Venn-Watson shared. "The critical nature of C150 became apparent as we realized that its deficiency could lead to accelerated aging processes."

Decade-long research conducted by her team highlighted the profound impact of C150 on human health. Their findings revealed that low levels of C150 in red blood cell membranes lead to fragile cells, which over time can cause liver complications and a novel type of cell death known as ferroptosis. Such interactions contribute to metabolic hyperferritinemia—a syndrome that may hasten declines in metabolic, liver, and cognitive functions as we age. Importantly, an independent research team has validated her hypothesis.

The science surrounding C150 is compelling; extensive cohort studies have illustrated a strong correlation between higher C150 levels and enhanced metabolic and cardiovascular health. An analysis indicated that a mere 0.1% rise in C150 correlates with a 32% reduction in risk for developing type 2 diabetes. Furthermore, the beneficial effects of C150 extend into early life; mothers with elevated C150 levels are positively linked with healthier developmental outcomes for their infants and children's cognitive growth.

In light of these discoveries, the Office of Naval Research provided funding for Dr. Venn-Watson and her husband, Eric—a Navy physician— to innovate within the nutritional supplement space. The outcome was fatty15, a pure C150 supplement engineered to support healthy aging. In just five years since its launch, this product has garnered more than 30 prestigious accolades, including recognitions from Fast Company and Inc. Magazine.

The relentless pursuit of quality and transparency in their product led fatty15 to undergo the industry’s most rigorous testing program, known as TESTED by SuppCo. This evaluation ensures that supplements meet or exceed 95% of their label claims, providing consumers with confidence in the products they use. Fatty15 proudly achieved an impressive TrustScore of 9.88 from SuppCo, ranking it among the top 1% of over 160,000 tested supplements, based on over 30 quality attributes.

As co-CEO, Dr. Eric Venn-Watson emphasizes the commitment to high standards. "The highest degree of transparency is vital to us. We are delighted to see fatty15 certified under the most rigorous industry standards."

In addition to her recent accolade, Dr. Venn-Watson's contributions to nutrition have gained attention through a TEDx Talk and her book, The Longevity Nutrient, which has reached bestseller status. Seraphina Therapeutics continues to challenge conventional nutritional narratives to create innovative health products designed for improved quality of life.

For further information on Fatty15 and its remarkable journey in advancing human health through essential nutrients, visit DiscoverC15.com and fatty15.com.